Based on these numbers, the researchers estimated that 5-year cumulative risks of recurrent events were 17.4% for ischemic ...

The annual risk of recurrent ischemic stroke in patients with atrial fibrillation (AF) is about 3.75%, despite around 92% of ...

Findings that LAARs are associated with plasma EVs suggest a mechanism by which EVs could facilitate LAAR ... This may account, in part, for observation of LAAR tissue damage independent of ...

"This research paves the way for innovative anticoagulation therapies by targeting ... More information: Rong Wang et al, Structure and mechanism of vitamin-K-dependent γ-glutamyl carboxylase ...

1 Anticoagulants are the current standard for prevention and ... DOACs can be classified by their mechanism of action into direct FXa inhibitors (rivaroxaban, apixaban, edoxaban, all including “xa” in ...

Current treatments rely on anticoagulants such as direct oral ... noting abelacimab’s dual mechanism of action and prior proof-of-concept data in thromboprophylaxis.

an oral anticoagulant prescribed to treat and prevent blood clots. NOACs target individual clotting proteins in the blood. Because these drugs have two different mechanisms of action in the body ...

Here, we summarise potential beneficial, non-anticoagulant mechanisms underlying treatment of COVID-19 patients with heparin/LMWH, which include: (i) Inhibition of heparanase activity, responsible for ...

This approach could revolutionize the use of anticoagulants in surgery or other applications. The mechanism of activation and deactivation of the active principle could also be used in immunotherapy.

called the experimental anticoagulant “promising,” especially since it works through a new mechanism. However, he emphasized that as with all anticoagulants, there is a risk of bleeding.